RET

RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.

RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.

Products Related to RET(32)

GC10035 TG101209
CAS: 936091-14-4
Purity: >99.50%
An inhibitor of JAK2, FLT3, RET, and JAK3
GC10111 Regorafenib
CAS: 755037-03-7
Purity: >99.00%
Regorafenib is an orally active multi-kinase inhibitor with IC 50 values of 13/4.2/46, 22, 7, 1.5 and 2.5nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
GC10914 AST 487
CAS: 630124-46-8
Purity: >99.00%
A multi-kinase inhibitor
GC14292 Apatinib Mesylate
CAS: 811803-05-1
Purity: >98.00%
Apatinib Mesylate blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.
GC14534 Regorafenib monohydrate
CAS: 1019206-88-2
Purity: >99.50%
A multi-kinase inhibitor
GC14606 Regorafenib hydrochloride
CAS: 835621-07-3
Purity: >99.50%
A multi-kinase inhibitor
GC15454 Lenvatinib (E7080)
CAS: 417716-92-8
Purity: >99.50%
E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.
GC16391 Amuvatinib (MP-470, HPK 56)
CAS: 850879-09-3
Purity: >98.00%
A multi-targeted RTK inhibitor
GC18492 GSK3179106
CAS: 1627856-64-7
Purity: >99.00%
A RET kinase inhibitor
GC19062 BBT594
CAS: 882405-89-2
Purity: >99.50%
BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.
GC31780 Pralsetinib (Blu667)
CAS: 2097132-94-8
Purity: >98.50%
Pralsetinib (Blu667) is a selective inhibitor of the rearranged during transfection (RET) kinase, indicated for the treatment of certain RET-altered positive tumors.
GC32797 AD80
CAS: 1384071-99-1
Purity: >99.50%
AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
GC33192 Selpercatinib
CAS: 2152628-33-4
Purity: >98%
A RET kinase inhibitor
GC33362 Amuvatinib hydrochloride (MP470 hydrochloride)
CAS: 1055986-67-8
Purity: >98%
Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
GC34159 Ilorasertib (ABT-348)
CAS: 1227939-82-3
Purity: >98%
Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
GC34509 BT-13
CAS: 924537-98-4
Purity: >99.50%
BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat.
GC34809 SPP-86
CAS: 1357349-91-7
Purity: >99.50%
SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase, with an IC50 of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.
GC36438 Lenvatinib mesylate
CAS: 857890-39-2
Purity: >99.00%
An inhibitor of VEGFR2 and VEGFR3
GC37047 Pz-1
CAS: 1800505-64-9
Purity: >99.00%
Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases.
GC37933 WHI-P180 hydrochloride
CAS: 153437-55-9
Purity: >98%
WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.
GC38519 Ilorasertib hydrochloride
CAS: 1847485-91-9
Purity: >98.50%
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
GC49686 N-desmethyl Regorafenib N-oxide
CAS: 835621-12-0
Purity: >90.00%
An active metabolite of regorafenib
GC60592 APS6-45
CAS: 2188236-41-9
Purity: >99.50%
APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.
GC64340 Zeteletinib
CAS: 2216753-97-6
Purity: >98%
Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity.

Category Product List
Catalog No.	Product Name	CAS No.	Purity
GC10035	TG101209	936091-14-4	>99.50%
GC10035	An inhibitor of JAK2, FLT3, RET, and JAK3
GC10111	Regorafenib	755037-03-7	>99.00%
GC10111	Regorafenib is an orally active multi-kinase inhibitor with IC 50 values of 13/4.2/46, 22, 7, 1.5 and 2.5nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
GC10914	AST 487	630124-46-8	>99.00%
GC10914	A multi-kinase inhibitor
GC14292	Apatinib Mesylate	811803-05-1	>98.00%
GC14292	Apatinib Mesylate blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.
GC14534	Regorafenib monohydrate	1019206-88-2	>99.50%
GC14534	A multi-kinase inhibitor
GC14606	Regorafenib hydrochloride	835621-07-3	>99.50%
GC14606	A multi-kinase inhibitor
GC15454	Lenvatinib (E7080)	417716-92-8	>99.50%
GC15454	E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.
GC16391	Amuvatinib (MP-470, HPK 56)	850879-09-3	>98.00%
GC16391	A multi-targeted RTK inhibitor
GC18492	GSK3179106	1627856-64-7	>99.00%
GC18492	A RET kinase inhibitor
GC19062	BBT594	882405-89-2	>99.50%
GC19062	BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.
GC31780	Pralsetinib (Blu667)	2097132-94-8	>98.50%
GC31780	Pralsetinib (Blu667) is a selective inhibitor of the rearranged during transfection (RET) kinase, indicated for the treatment of certain RET-altered positive tumors.
GC32797	AD80	1384071-99-1	>99.50%
GC32797	AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
GC33192	Selpercatinib	2152628-33-4	>98%
GC33192	A RET kinase inhibitor
GC33362	Amuvatinib hydrochloride (MP470 hydrochloride)	1055986-67-8	>98%
GC33362	Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
GC34159	Ilorasertib (ABT-348)	1227939-82-3	>98%
GC34159	Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
GC34509	BT-13	924537-98-4	>99.50%
GC34509	BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat.
GC34809	SPP-86	1357349-91-7	>99.50%
GC34809	SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase, with an IC50 of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.
GC36438	Lenvatinib mesylate	857890-39-2	>99.00%
GC36438	An inhibitor of VEGFR2 and VEGFR3
GC37047	Pz-1	1800505-64-9	>99.00%
GC37047	Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases.
GC37933	WHI-P180 hydrochloride	153437-55-9	>98%
GC37933	WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.
GC38519	Ilorasertib hydrochloride	1847485-91-9	>98.50%
GC38519	Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
GC49686	N-desmethyl Regorafenib N-oxide	835621-12-0	>90.00%
GC49686	An active metabolite of regorafenib
GC60592	APS6-45	2188236-41-9	>99.50%
GC60592	APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.
GC64340	Zeteletinib	2216753-97-6	>98%
GC64340	Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity.